Quantcast

Latest Trubion Stories

2010-09-08 15:00:00

SEATTLE, Sept. 8 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that the U.S. Department of Justice and Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act"), as amended, with respect to the planned acquisition of Trubion by Emergent BioSolutions Inc. (NYSE: EBS) announced on Aug. 12, 2010. Accordingly, the requirement under the merger agreement for the...

2010-08-16 15:00:00

SEATTLE, Aug. 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced financial results for its second quarter and six months ended June 30, 2010. (Logo: http://photos.prnewswire.com/prnh/20090320/TRUBIONLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) Second-Quarter and First-Half 2010 Financial Results Revenue for the second quarter and six months ended June 30, 2010, increased to $5.7 million and $11.2 million, respectively,...

2010-08-13 06:00:00

SEATTLE, Aug. 13 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the second quarter and first six months ended June 30, 2010, after the close of market on Aug. 16, 2010. The company's earnings conference call will take place Aug. 16, 2010, at 2 p.m. Pacific Time, 5 p.m. Eastern Time. (Logo: http://photos.prnewswire.com/prnh/20090320/TRUBIONLOGO) (Logo:...

2010-08-12 15:15:00

SEATTLE, Aug. 12 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced the signing of a definitive merger agreement with Emergent BioSolutions Inc. (NYSE: EBS), in which Emergent has agreed to acquire Trubion. Under the terms of the agreement, each share of Trubion common stock will be converted into the right to receive an upfront payment of $1.365 per share in cash and 0.1641 shares of Emergent BioSolutions common stock. The upfront payment represents a...

2010-06-14 15:00:00

SEATTLE, June 14 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in...

2010-06-03 15:00:00

SEATTLE, June 3 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that the Board of Appeal for the European Patent Office (EPO) has upheld the Opposition Division's original decision (announced Sept. 11, 2008) to revoke Genentech and Biogen Idec's European Patent 1176981, generally directed to the use of an anti-CD20 antibody for the treatment of rheumatoid arthritis (RA). The revocation of the patent claims as originally granted is now final. (Logo:...

2010-06-01 15:00:00

SEATTLE, June 1 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced it will present a corporate update at the 9th Annual Needham Healthcare Conference to be held at the New York Palace Hotel, 455 Madison Avenue in New York City. Michelle Burris, senior vice president and chief operating officer, and John Bencich, vice president and chief financial officer, are scheduled to present on Thursday, June 10 at 2:40 pm ET in the Henry conference room (5th floor)....

2010-05-12 15:00:00

SEATTLE, May 12 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both...

2010-05-06 15:00:00

SEATTLE, May 6 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced financial results for its first-quarter ended March 31, 2010. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) First-Quarter 2010 Financial Results Revenue for the first quarter of 2010 was $5.5 million compared with $4.2 million for the first quarter of 2009. Revenue was primarily earned through Trubion's strategic collaborations with Pfizer for the development of...

2010-04-29 15:00:00

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the first quarter ended March 31, 2010, after the close of market on May 6, 2010. The company's earnings conference call will take place May 6, 2010 at 2 p.m. Pacific Time, 5 p.m. Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) Both live events will be available for viewing on Trubion's website at...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related